Petros Grivas, MD, PhD, joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer, including enfortumab vedotin (EV) and the results of the drug’s EV-301 trial. The combination treatment of EV and pembrolizumab versus chemotherapy alone is also discussed, including the EV-302 trial. ...
The Uromigos
The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.
View our exclusive coverage of The Uromigos Live & Unplugged in Nashville, Tennessee, held September 30 through October 1, including panel discussions with experts on kidney, prostate, and bladder cancers.
Advertisement
Latest Episode
Advertisement
A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference.
A summary of the renal cancer session of the Conversations & Trending Topics in GU Cancers conference in the Canary Islands.
Sam Chang, MD, MBA, joins The Uromigos to discuss the results of IL-15RαFc superagonist N-803 for papillary NMIBC.
Chris Sweeney, MBBS, joins The Uromigos to discuss 2022 research as well as further studies to be carried out in 2023.
Monty Pal, MD, FASCO, discusses his recent study on the use of novel CAR T-cell therapy for renal cell carcinoma.
Episode 210: Christmas Prostate Debate - Olaparib and Abiraterone in Selected or Unselected Patients
Drs. Silke Gillessen and Dan George debate the use of olaparib and abiraterone in selected or unselected patients with mCRPC.ESMO Coverage
ESMO 2022: Enfortumab Vedotin Plus Pembrolizumab Versus Pembrolizumab Alone for Urothelial Carcinoma
Peter O'Donnell describes the randomized phase 2 study on enfortumab vedotin and pembrolizumab against pembrolizumab alone.Nizar Tannir describes this randomized phase 3 study on bempegaldesleukin plus nivolumab as presented at ESMO.
The phase III PRESTO study examined the effects of androgen suppressants on biochemically relapsed prostate cancer.
Axel Bex summarizes the ipi/nivo, pembro and atezo studies that were presented at ESMO 2022.
Paper of the Month
Syed Hussain and Sam Funt describe their studies on this topic.
Martin Stockler describes the ENZAMET trial, which shows mixed effects of enza on QOL in prostate cancer.
Yelena Janjigian describes ipi/nivo versus nivo chemo versus chemo in gastric cancer.
Elizabeth de Vries describes her paper on this topic published in Annals of Oncology.
Dr. Brian Rini’s Disclosures
Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis
Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai
Stock: PTC therapeutics
